CST, 3273S, JARID1B Antibody

Polyclonal Antibody for studying JARID1B. Validated for Western Blotting,Immunoprecipitation. Available in 2 sizes. Highly specific and rigorously validated in-house, JARID1B Antibody (CST #3273) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation Specificity / Sensitivity JARID1B Antibody detects endogenous levels of JARID1B protein. This antibody does not cross-react with other JARID proteins, including JARID1A, JARID1C and JARID1D. Species Reactivity: Human, Monkey Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to the human JARID1B protein. Antibodies are purified by protein A and peptide affinity chromatography. Background The methylation state of lysine residues in histone proteins is a major determinant for formation of active and inactive regions of the genome and is crucial for proper programming of the genome during development (1,2). Jumonji C (JmjC) domain-containing proteins represent the largest class of potential histone demethylase proteins (3). The JmjC domain can catalyze the demethylation of mono-, di-, and tri-methyl lysine residues via an oxidative reaction that requires iron and α-ketoglutarate (3). Based on homology, both humans and mice contain at least 30 such proteins, which can be divided into 7 separate families (3). The JARID (Jumonji/AT-rich interactive domain-containing protein) family contains four members: JARID1A (also RBP2 and RBBP2), JARID1B (also PLU-1), JARID1C (also SMCX), and JARID1D (also SMCY) (4). In addition to the JmJC domain, these proteins contain JmJN, BRIGHT, C5HC2 zinc-finger, and PHD domains, the latter of which binds to methylated histone H3 (Lys9) (4). All four JARID proteins demethylate di- and tri-methyl histone H3 Lys4; JARID1B also demethylates mono-methyl histone H3 Lys4 (5-7). JARID1A is a critical RB-interacting protein and is required for Polycomb-Repressive Complex 2 (PRC2)-mediated transcriptional repression during ES cell differentiation (8). A JARID1A-NUP98 gene fusion is associated with myeloid leukemia (9). JARID1B, which interacts with many proteins including c-Myc and HDAC4, may play a role in cell fate decisions by blocking terminal differentiation (10-12). JARID1B is overexpressed in many breast cancers and may act by repressing multiple tumor suppressor genes, including and (13,14). JARID1C has been found in a complex with HDAC1, HDAC2, G9a, and REST, which binds to and represses REST target genes in non-neuronal cells (7). JARID1C mutations are associated with X-linked mental retardation and epilepsy (15,16). JARID1D is uniquely localized to the Y chromosome, and functions as a tumor suppressor by repressing genes associated with cell invasiveness (17). JARID1D is frequently mutated in metastatic prostate tumors, and low JARID1D levels are associated with poor prognosis in prostate cancer patients (17). Alternate Names [histone H3]-trimethyl-L-lysine(4) demethylase 5B; Cancer/testis antigen 31; CT31; FLJ10538; FLJ12459; FLJ12491; FLJ16281; FLJ23670; Histone demethylase JARID1B; JARID1B; jumonji, AT rich interactive domain 1B; Jumonji/ARID domain-containing protein 1B; KDM5B; lysine (K)-specific demethylase 5B; lysine demethylase 5B; Lysine-specific demethylase 5B; MRT65; PLU-1; PLU1; PPP1R98; protein phosphatase 1, regulatory subunit 98; PUT1; putative DNA/chromatin binding motif; RBBP2H1; RBBP2H1A; RBP2-H1; RBP2-like; Retinoblastoma-binding protein 2 homolog 1; retinoblastoma-binding protein 2, homolog 1A Specification REACTIVITY: H Mk SENSITIVITY: Endogenous MW (kDa): 180 SOURCE: Rabbit